Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsASX:CUV -2.06%81 3-Year ROIIC % is 57.18 as of Jun. 2025, which is 25% below its 10-year median of 75.74. GuruFocus rates ASX:CUV with a GF Score™ of 81/100 and a GF Value™ of A$17.77 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,322 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 72.69% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Clinuvel Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 57.18%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Clinuvel Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
ASX:CUV's 3-Year ROIIC % is ranked better than 72.69% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs ASX:CUV: 57.18
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Clinuvel Pharmaceuticals 3-Year ROIIC % Related Terms
Clinuvel Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CUV vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Clinuvel Pharmaceuticals (ASX:CUV) has a 3-Year ROIIC % of 57.18 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 25% below median its historical median of 75.74. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #361 out of 1322 companies in the Biotechnology industry, placing it in the top 27.3%.
Is Clinuvel Pharmaceuticals' 3-Year ROIIC % too high?
Clinuvel Pharmaceuticals' current 3-Year ROIIC % of 57.18 is 25% below median its 10-year median of 75.74. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #361 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #361 out of 1322 companies for 3-Year ROIIC %. This puts Clinuvel Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current 3-Year ROIIC % is 57.18, which is 25% below median its own 10-year median of 75.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.77, compared to a current price of A$9.98 — trading 43.8% below its estimated fair value. The current 3-Year ROIIC % is 57.18, which is 25% below median its 10-year median of 75.74. Clinuvel Pharmaceuticals' overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current 3-Year ROIIC % is 57.18 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$9.98 is trading 43.8% below its estimated GF Value™ of A$17.77.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
3-Year ROIIC %: 57.18 (25% below median its 10-year median of 75.74)
GF Value™: A$17.77 vs. price of A$9.98 (43.8% below fair value)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
81GF Score
Get the complete analysis for ASX:CUV
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
